VIP and PACAP as Regulators of Immunity: New Perspectives from A Receptor Point of ViewCatalina Abad and Yossan-Var Tan*
Inserm U905, University of Rouen, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, Normandy, France
- *Corresponding Author:
- Yossan-Var Tan
Inserm U905 University of Rouen Institute for Research and Innovation in Biomedicine (IRIB) Rouen
E-mail: [email protected]
Received date: Feb 11, 2016; Accepted date: Mar 12, 2016; Published date: Mar 15, 2016
Citation: Abad C, Var Tan Y (2016) VIP and PACAP as Regulators of Immunity: New Perspectives from A Receptor Point of View. J Clin Exp Neuroimmunol 1:104. doi:10.4172/jceni.1000104
Copyright: © 2016 Abad C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) are two neuropeptides acting through three common G-protein coupled receptors (VPAC1, VPAC2 and PAC1). Among their pleiotropic actions within the organism, VIP and PACAP are known to exhibit immunomodulatory properties in both the innate and adaptive immune axes. The fact that they inhibit inflammation in murine models of disease has brought these peptides into the spotlight within the field of therapeutic discovery for autoimmune/inflammatory diseases. Pharmacological tools and transgenic mice have been useful in order to investigate the involvement of each of their three receptors in these actions. This review focuses on the relevance of the VPAC2 receptor on VIP and PACAP modulation of immune responses, and discusses its potential as a target for the treatment of Th1-driven inflammatory disorders.